Salvatore Caponnetto

Prof. Dr. Salvatore Caponnetto

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2016 in Scientific Reports
Verified
Journal Article
Open access
CNChiara Nicolazzo
Chiara Nicolazzo
CRCristina Raimondi
Cristina Raimondi
MMMariaLaura Mancini
MariaLaura Mancini
SCSalvatore Caponnetto
Salvatore Caponnetto
AGAngela Gradilone
Angela Gradilone
PGPaola Gazzaniga
Paola Gazzaniga
Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration. Liquid biopsy might allow real-time sampling of patients for PD-L1 through the course of the disease. Twenty-four stage IV NSCLC patients included in the Expanded Access Program with Nivolumab were enrolled. Circulating tumor cells (CTCs) were analyzed by CellSearch with anti-human B7-H1/PD-L1 PE-conjugated antibody. PD-L1 expressing CTCs were assessed at baseline, at 3 and 6 months after starting therapy, and correlated with outcome. At baseline and at 3 months of treatment, the presence of CTCs and the expression of PD-L1 on their surface were found associated to poor patients outcome. Nevertheless, the high frequency of PD-L1 expressing CTCs hampered to discriminate the role of PD-L1 in defining prognosis. Conversely although CTCs were found in all patients 6 months after treatment, at this time patients could be dichotomized into two groups based PD-L1 expression on CTCs. Patients with PD-L1 negative CTCs all obtained a clinical benefit, while patients with PD-L1 (+) CTCs all experienced progressive disease. This suggests that the persistence of PD-L1(+) CTCs might mirror a mechanism of therapy escape.

1 September 2019 in Surgical Oncology
Verified
Journal Article
Closed access
AGalain gelibter
alain gelibter
SCSalvatore Caponnetto
Salvatore Caponnetto
FUFederica Urbano
Federica Urbano
AEAlessandra Emiliani
Alessandra Emiliani
SSSimone Scagnoli
Simone Scagnoli
ECEnrico Cortesi
Enrico Cortesi

29 December 2015 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
IZIlaria Grazia Zizzari
Ilaria Grazia Zizzari
CNChiara Napoletano
Chiara Napoletano
FBFederico Battisti
Federico Battisti
HRHassan Rahimi
Hassan Rahimi
SCSalvatore Caponnetto
Salvatore Caponnetto
ARAurelia Rughetti
Aurelia Rughetti
C-type lectin receptors (CLRs) on antigen-presenting cells (APCs) facilitate uptake of carbohydrate antigens for antigen presentation, modulating the immune response in infection, homeostasis, autoimmunity, allergy, and cancer. In this review, we focus on the role of the macrophage galactose type C-type lectin (MGL) in the immune response against self-antigens, pathogens, and tumor associated antigens (TAA). MGL is a CLR exclusively expressed by dendritic cells (DCs) and activated macrophages (MØs), able to recognize terminal GalNAc residues, including the sialylated and nonsialylated Tn antigens. We discuss the effects on DC function induced throughout the engagement of MGL, highlighting the importance of the antigen structure in the modulation of immune response. Indeed modifying Tn-density, the length, and steric structure of the Tn-antigens can result in generating immunogens that can efficiently bind to MGL, strongly activate DCs, mimic the effects of a danger signal, and achieve an efficient presentation in HLA classes I and II compartments.

1 August 2011 in Cytokine
Verified
Journal Article
Closed access
Alessandra NicolettiAlessandra Nicoletti
Alessandra Nicoletti
Paolo FagonePaolo Fagone
Paolo Fagone
GDGiulia Donzuso
Giulia Donzuso
KMKatia Mangano
Katia Mangano
VDValeria Dibilio
Valeria Dibilio
Ferdinando NicolettiFerdinando Nicoletti
Ferdinando Nicoletti

17 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MTMarta Tenuta
Marta Tenuta
AGalain gelibter
alain gelibter
CPCarla Pandozzi
Carla Pandozzi
GSGrazia Sirgiovanni
Grazia Sirgiovanni
Federica CampoloFederica Campolo
Federica Campolo
ESEmilia Sbardella
Emilia Sbardella
Background: Sarcopenia is a condition characterized by loss of skeletal muscle mass associated with worse clinical outcomes in cancer patients. Data on sarcopenia in patients undergoing immune checkpoint inhibitors (ICI) therapy are still limited. The aim of this prospective observational study was to investigate the relationship between sarcopenia, ICI treatment response and immunological profile, in patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-seven stage IV NSCLC patient candidates for starting ICI, were enrolled from the Policlinico Umberto I outpatient Oncology. Patients underwent baseline blood test, inflammatory markers, cytokine assessment and body composition with dual-energy X-ray absorptiometry (DXA). Sarcopenia was defined with appendicular skeletal muscle mass over height2 (ASM/heigh2). Results: Overall, 19/47 patients (40.4%) results were sarcopenic. Sarcopenic patients showed significantly shorter PFS than non-sarcopenic ones (20.3 weeks, 95% CI 7.5–33.1 vs. 61 weeks, 95% CI 22.5–99.4, p = 0.047). Specifically, they had an 8.1 times higher risk of progression disease (PD) than non-sarcopenic patients (OR 8.1, 95%, p = 0.011). Conclusions: Sarcopenic patients showed worse PFS and had a higher risk of PD compared to non-sarcopenic ones. Therefore, sarcopenia may reflect the increased metabolic activity of more aggressive tumors, which involves systemic inflammation and muscle wasting and could be considered a negative predictive factor for ICI response.

8 February 2016 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
MAMorena Antonilli
Morena Antonilli
HRHassan Rahimi
Hassan Rahimi
VVValeria Visconti
Valeria Visconti
CNChiara Napoletano
Chiara Napoletano
IRIlary Ruscito
Ilary Ruscito
MNMarianna Nuti
Marianna Nuti
Vaccination with priming and expansion of tumour reacting T cells is an important therapeutic option to be used in combination with novel checkpoint inhibitors to increase the specificity of the T cell infiltrate and the efficacy of the treatment. In this phase I/II study, 14 high-risk disease-free ovarian (OC) and breast cancer (BC) patients after completion of standard therapies were vaccinated with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA-A2+-restricted peptides and Montanide. Patients were subjected to 6 doses of vaccine every two weeks and a recall dose after 3 months. ECOG grade 2 toxicity was observed at the injection site. Eight out of 14 patients showed specific CD8+ T cells to at least one antigen. None of 4 patients vaccinated for compassionate use showed a CD8 activation. An OC patient who suffered from a lymph nodal recurrence, showed specific anti-ErbB2 CD8+ T cells in the bulky aortic lymph nodes suggesting homing of the activated T cells. Results confirm that peptide vaccination strategy is feasible, safe and well tolerated. In particular OC patients appear to show a higher response rate compared to BC patients. Vaccination generates a long-lasting immune response, which is strongly enhanced by recall administrations. The clinical outcome of patients enrolled in the trial appears favourable, having registered no deceased patients with a minimum follow-up of 8 years. These promising data, in line with the results of similar studies, the high compliance of patients observed and the favourable toxicity profile, support future trials of peptide vaccination in clinically disease-free patients who have completed standard treatments.